-
1
-
-
78649486856
-
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
-
H. Kantarjian, F. Ravandi, S. O'Brien Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 2010 4422 4429
-
(2010)
Blood
, vol.116
, pp. 4422-4429
-
-
Kantarjian, H.1
Ravandi, F.2
O'Brien, S.3
-
2
-
-
34249810897
-
Acute myeloid leukemia and myelodysplastic syndromes in older patients
-
E. Estey Acute myeloid leukemia and myelodysplastic syndromes in older patients J Clin Oncol 25 2007 1908 1915
-
(2007)
J Clin Oncol
, vol.25
, pp. 1908-1915
-
-
Estey, E.1
-
3
-
-
66149148673
-
Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
-
G. Juliusson, P. Antunovic, A. Derolf Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 113 2009 4179 4187
-
(2009)
Blood
, vol.113
, pp. 4179-4187
-
-
Juliusson, G.1
Antunovic, P.2
Derolf, A.3
-
4
-
-
0035397980
-
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
-
E.L. Sievers, R.A. Larson, E.A. Stadtmauer Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244 3254
-
(2001)
J Clin Oncol
, vol.19
, pp. 3244-3254
-
-
Sievers, E.L.1
Larson, R.A.2
Stadtmauer, E.A.3
-
5
-
-
25144485908
-
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
-
R.A. Larson, E.L. Sievers, E.A. Stadtmauer Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 104 2005 1442 1452
-
(2005)
Cancer
, vol.104
, pp. 1442-1452
-
-
Larson, R.A.1
Sievers, E.L.2
Stadtmauer, E.A.3
-
6
-
-
27144464151
-
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
-
S. Amadori, S. Suciu, R. Stasi Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups Leukemia 19 2005 1768 1773
-
(2005)
Leukemia
, vol.19
, pp. 1768-1773
-
-
Amadori, S.1
Suciu, S.2
Stasi, R.3
-
7
-
-
77950796567
-
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)
-
S. Amadori, S. Suciu, D. Selleslag Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19) Br J Haematol 149 2010 376 382
-
(2010)
Br J Haematol
, vol.149
, pp. 376-382
-
-
Amadori, S.1
Suciu, S.2
Selleslag, D.3
-
8
-
-
77957711298
-
Preliminary results of Southwest Oncology Group Study SO106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy to previously untreated acute myeloid leukemia
-
S. Petersdorf, K. Kopecky, R.K. Stuart Preliminary results of Southwest Oncology Group Study SO106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy to previously untreated acute myeloid leukemia Blood 114 2009 326a
-
(2009)
Blood
, vol.114
-
-
Petersdorf, S.1
Kopecky, K.2
Stuart, R.K.3
-
9
-
-
10744230708
-
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
-
W.J. Kell, A.K. Burnett, R. Chopra A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 102 2003 4277 4283
-
(2003)
Blood
, vol.102
, pp. 4277-4283
-
-
Kell, W.J.1
Burnett, A.K.2
Chopra, R.3
-
10
-
-
79952099282
-
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial
-
A.K. Burnett, R.K. Hills, D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
-
(2011)
J Clin Oncol
, vol.29
, pp. 369-377
-
-
Burnett, A.K.1
Hills, R.K.2
Milligan, D.3
-
11
-
-
84860121680
-
The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial
-
A.K. Burnett, R.K. Hills, A.E. Hunter The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial Blood 118 2011 582a
-
(2011)
Blood
, vol.118
-
-
Burnett, A.K.1
Hills, R.K.2
Hunter, A.E.3
-
12
-
-
84860176499
-
Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: A prospective randomized phase 3 trial from the acute leukemia French association (ALFA)
-
S. Castaigne, C. Pautas, C. Terre Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: a prospective randomized phase 3 trial from the acute leukemia French association (ALFA) Blood 118 2011 6a
-
(2011)
Blood
, vol.118
-
-
Castaigne, S.1
Pautas, C.2
Terre, C.3
-
13
-
-
77449159028
-
Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
-
H. Döhner, E.H. Estey, S. Amadori Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
-
(2010)
Blood
, vol.115
, pp. 453-474
-
-
Döhner, H.1
Estey, E.H.2
Amadori, S.3
-
14
-
-
79956369016
-
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
-
H.F. Fernandez, Z. Sun, M.R. Litzow Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin Blood 117 2011 3506 3513
-
(2011)
Blood
, vol.117
, pp. 3506-3513
-
-
Fernandez, H.F.1
Sun, Z.2
Litzow, M.R.3
-
15
-
-
84859502851
-
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: A randomized phase II trial in elderly patients
-
U. Brunnberg, M. Mohr, R. Noppeney Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients Ann Oncol 23 2012 990 996
-
(2012)
Ann Oncol
, vol.23
, pp. 990-996
-
-
Brunnberg, U.1
Mohr, M.2
Noppeney, R.3
-
16
-
-
70349451999
-
High-dose daunorubicin in older patients with acute myeloid leukemia
-
B. Löwenberg, G.J. Ossenkoppele, W. van Putten High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
-
(2009)
N Engl J Med
, vol.361
, pp. 1235-1248
-
-
Löwenberg, B.1
Ossenkoppele, G.J.2
Van Putten, W.3
|